Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Biohaven Ltd. (BHVN)

Pharmaceutical Preparations

https://www.biohavenpharma.com

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.

215 CHURCH STREET
NEW HAVEN, CT

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

09/23/2022

Market Cap

3,610,568,528

Shares Outstanding

80,230,000

Weighted SO

80,233,656

Total Employees

N/A

Upcoming Earnings

07/29/2024

Similar Tickers

IMNM --.--%

INBX --.--%

AGE --.--%

ICVX --.--%

DAWN --.--%

TERN --.--%

XFOR --.--%

INZY --.--%

MREO --.--%

Beta

4.1740

Last Div

0.0000

Range

16.45-62.21

Chg

-1.0800

Avg Vol

1143795

Mkt Cap

3610568528

Exch

NYSE

Country

US

Phone

203 404 0410

DCF Diff

35.0164

DCF

3.0736

Div Yield

0.0000

P/S

0.0000

EV Multiple

-4.3692

P/FV

8.7345

Div Yield %

0.0000

P/E

-4.4894

PEG

-0.0815

Payout

0.0000

Current Ratio

3.2730

Quick Ratio

3.2730

Cash Ratio

1.5320

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

1692.0588

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

0.0050

ROA

-1.2814

ROE

-2.1283

ROCE

-1.8321

NI/EBT

0.9950

EBT/EBIT

0.9604

EBIT/Rev

0.0000

Debt Ratio

0.0510

D/E

0.0775

LT Debt/Cap

0.0639

Total Debt/Cap

0.0719

Int Coverage

0.0000

CF/Debt

-16.1426

Equity Multi

1.5183

Rec Turnover

0.0000

Pay Turnover

0.2157

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-5.4706

FCF/Share

-5.5287

Cash/Share

4.9803

OCF/Sales

0.0000

FCF/OCF

1.0106

CF Coverage

-16.1426

ST Coverage

-135.2476

CapEx Coverage

-94.0139

Div&CapEx Cov

-94.0139

P/BV

8.7345

P/B

8.7345

P/S

0.0000

P/E

-4.4894

P/FCF

-7.4409

P/OCF

-6.9810

P/CF

-6.9810

PEG

-0.0815

P/S

0.0000

EV Multiple

-4.3692

P/FV

8.7345

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 25, 00:52 ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BHVN GlobeNewswire Inc. Jul 17, 23:02 BIOHAVEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biohaven Ltd. and Encourages Investors to Contact the Firm Benzinga Jul 17, 01:07 Securities Fraud Investigation Into Biohaven Ltd. (BHVN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz The Motley Fool May 15, 22:03 Why Biohaven Stock Dove by Nearly 20% on Thursday The Motley Fool Apr 25, 21:10 Why Biohaven Stock Plummeted by More Than 15% Today Benzinga Apr 14, 02:04 BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm GlobeNewswire Inc. Jan 13, 01:04 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs MarketWatch Dec 28, 07:46 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky MarketWatch Dec 28, 06:34 Here's a 'solid contrarian idea' for 2024, according to BTIG's Krinsky

Revenue Product Segmentation